Free content
-
Credit Suisse First Boston in London has hired Toby Ali, executive director in leveraged finance at Lehman Brothers in London, as a director in leveraged finance origination.
-
Credit Suisse First Boston has hired Mychal Harrison, associate at Goldman Sachs, as v.p. in high-yield trading.
-
Fischer Francis Trees & Watts is increasing its holdings of 10-year U.S. TIPS and will finance the move by selling off the short and long parts of the U.S. TIPS curve.
-
Despite the recent widening in high-yield new issue spreads, coupons still have room to rise before reaching fair value by historical standards, said John Lonski, chief economist at Moody's Investors Service.
-
Ravi Joseph, managing director at Goldman Sachs in London and a veteran of the European securitization markets, has left the firm after joining from Morgan Stanley less than one year ago. The
-
London-based hedge fund Picus Capital Management has hired Matthew Robbins, v.p. in credit research at Dresdner Kleinwort Wasserstein in London, as an investment specialist.
-
Katonah Capital, the loan asset management subsidiary of Kohlberg & Co., has proposed that Sankaty Advisors, Blackstone Debt Advisors and INVESCO Senior Secured Management act as the replacement managers for a group of Katonah funds, potentially locking up more than $2 billion in assets that have been in play for the last month.
-
Morgan Edwards, managing director at Bear Stearns, explaining why he wanted to join the banks leveraged finance arm.
-
Lehman Brothers has arranged a $600 million collateralized loan obligation for Ares Capital Management called Ares IX CLO that uses the bank's Par structure.
-
A potential takeover of Meridian Automotive Systems by a financial sponsor and another auto-parts company is driving trading in the company's $165 million second lien.
-
A total of $1.5 billion was liquidated from high-yield mutual funds in the week ending March 23, marking the heftiest departure from the asset class in 10 months and the sixth consecutive week of outflows.
-
Nellson Neutraceutical's bank debt has softened with the $285 million first-lien loan trading around 95-96 and the $75 million second lien quoted at 87.